Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis

Completed · Not applicable · Has a placebo group

Conditions studied: Psoriasis, Psoriatic Arthritis

In brief

This is a proof-of-principle, placebo-controlled, open label study to assess the improvement in the Treg counts and PASI Scores with PEVCO given at 1000 mg four times daily in patients with PsO (subjects may or may not have PsA) , who have active disease and are not currently receiving other therapy (as defined by the inclusion/exclusion criteria) compared to healthy subjects. The patients and healthy controls will receive placebo or PEVCO for a total of 9 weeks (3 weeks for placebo, followed by 6 weeks for PEVCO). No topical or systemic medications will be used during this period.

Key facts

Study ID
NCT03409211
Run by
NYU Langone Health
People needed
22
Starts
2017-12-12
Expected to finish
2019-09-30
Last updated by the study team
2020-12-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.